Advertisement
Advertisement

INSM

INSM logo

Insmed, Inc.

109.53
USD
Sponsored
+1.62
+1.50%
May 21, 16:00 UTC -4
Closed
exchange

After-Market

110.44

+0.91
+0.83%

INSM Earnings Reports

Positive Surprise Ratio

INSM beat 16 of 42 last estimates.

38%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$405.40M
/
-$0.82
Implied change from Q1 26 (Revenue/ EPS)
+32.50%
/
+7.89%
Implied change from Q2 25 (Revenue/ EPS)
+277.42%
/
-51.76%

Insmed, Inc. earnings per share and revenue

On May 07, 2026, INSM reported earnings of -0.76 USD per share (EPS) for Q1 26, beating the estimate of -0.97 USD, resulting in a 22.34% surprise. Revenue reached 305.96 million, compared to an expected 309.36 million, with a -1.10% difference. The market reacted with a -23.41% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.82 USD, with revenue projected to reach 405.40 million USD, implying an increase of 7.89% EPS, and increase of 32.50% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
logo
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
logo
TuHURA Biosciences, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-10.83%
logo
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-
Actual
-$4.76
Surprise
-
logo
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
logo
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
logo
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
logo
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
logo
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
logo
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
For Q1 2026, Insmed, Inc. reported EPS of -$0.76, beating estimates by 22.34%, and revenue of $305.96M, -1.1% below expectations.
The stock price moved down -23.41%, changed from $137.09 before the earnings release to $105.00 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 10 analysts, Insmed, Inc. is expected to report EPS of -$0.82 and revenue of $405.40M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement